Abstract
A pressing challenge for genomic medicine services is to increase the diagnostic rate of molecular testing. Reanalysis of genomic data can increase the diagnostic yield of molecular testing for rare diseases by 5.9-47% and novel gene-disease associations are often cited as the catalyst for significant findings. However, clinical services lack adequate resources to conduct routine reanalysis for unresolved cases. To determine whether an automated application could lead to new diagnoses and streamline routine reanalysis, we developed TierUp. TierUp identifies new gene-disease associations with implications for unresolved rare disease cases recruited to the 100,000 Genomes Project. TierUp streams data from the public PanelApp database to enable routine, up-to-date reanalyses. When applied to 948 undiagnosed rare disease cases, TierUp highlighted 410 high and moderate impact variants in under 77 minutes, reducing the burden of variants for review with this reanalysis strategy by 99%. Ongoing variant interpretation has produced five follow-up clinical reports, including a molecular diagnosis of a rare form of spondylometaphyseal dysplasia. We recommend that clinical services leverage bioinformatics expertise to develop automated reanalysis tools. Additionally, we highlight the need for studies focused on the ethical, legal and health economics considerations raised by automated reanalysis tools.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N.E.M conducted this research while enrolled on the NHS Scientist Training programme which is funded by Health Education England.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Manchester, Guy's & St Thomas' NHS FT and Viapath
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Notification The authors declare that there is no conflict of interest.
Data Availability
All code is available https://github.com/NHS-NGS/JellyPy
